AN2 Therapeutics opened higher at $4.48, compared with its previous close of $4.46. In the last trading session, the stock traded between $4.34 and $4.75. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in AN2 Therapeutics is now worth
$ 28.90
Resulting in a loss of
$ 71.10 (71.10%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.01 (-0.20%)
Day High
$4.75
Day Low
$4.34
Day Open
$4.48
Prev Close
$4.46
Volume
1,66,532
1W Return
4.88%
1M Return
3.63%
3M Return
-24.35%
6M Return
-5.70%
1Y Return
270.92%
Fundamentals
Market Cap ($ Mn)
169
PE Ratio
-
PB Ratio
2.67
PEG Ratio
-
ROE
-52.12%
ROCE
-56.44%
EPS (TTM)
$-0.21
Investment Returns
1 Week
4.88%
1 Month
3.63%
3 Months
-24.35%
6 Months
-5.70%
9 Months
304.64%
Financials
Quarterly
All values in $ Mn
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
0.0
Sep 26
Updates
17Sep
AN2 Therapeutics grants $5.36 strike options and RSUs to new CMO
AN2 Therapeutics granted inducement equity awards to new CMO Cameron Trenor. Package includes options for 233,333 shares at $5.36 and 116,667 RSUs. Options vest over four years with a 25% cliff on the first anniversary. Grants approved under NASDAQ Rule 5635(c)(4) on September 15, 2026.
1mo ago
1Sep
AN2 Therapeutics to present epetraborole PV data at SOHO 2026
AN2 Therapeutics to present four abstracts on epetraborole at SOHO 2026. Data covers clinical and nonclinical findings for polycythemia vera treatment. Meeting held September 9-12, 2026, in Houston, Texas. Highlights include exposure-response relationships and safety profiles.
2mo ago
24Aug
AN2 Therapeutics appoints Cameron Trenor as chief medical officer
AN2 Therapeutics appoints Cameron Trenor as Chief Medical Officer. Dr. Trenor brings over 20 years of experience in clinical drug development. He succeeds co-founder George H. Talbot, who remains a strategic advisor. Company plans three Phase 2 studies to be active in 2026.
2mo ago
12Aug
AN2 Therapeutics Q2 EPS of $(0.18) beats estimates
AN2 Therapeutics beat Q2 EPS estimates with a loss of $(0.18) per share vs $(0.27) expected. Net loss widened to $8.2 million due to increased R&D, but strong cash reserves support operations through 2029.
3mo ago
20Jul
Guggenheim initiates coverage on AN2 Therapeutics with Buy rating
Guggenheim analyst Brad Canino has initiated coverage on AN2 Therapeutics with a Buy rating and a price target of $9, indicating a positive outlook.
